How to buy Paratek Pharmaceuticals stock (PRTK)

Paratek Pharmaceuticals is a biotechnology business based in the US. Paratek Pharmaceuticals shares (PRTK) are listed on the NASDAQ and all prices are listed in US Dollars. Paratek Pharmaceuticals employs 268 staff and has a trailing 12-month revenue of around $177 million.

Our top picks for where to buy Paratek Pharmaceuticals stock

Buy Paratek Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Paratek Pharmaceuticals stock price (NASDAQ: PRTK)

Use our graph to track the performance of PRTK stocks over time.

Paratek Pharmaceuticals shares at a glance

• Key figures

Information last updated 2023-11-19.

52-week range	$0.00 - $0.00
50-day moving average more info button	$2.20
200-day moving average more info button	$2.08
Wall St. target price	$2.15
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-1.11

Is it a good time to buy Paratek Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Paratek Pharmaceuticals financials

Revenue TTM	$177 million
Gross profit TTM	$99.4 million
Return on assets TTM	-17.99%
Return on equity TTM	0%
Profit margin	-35.44%
Book value	$-3.52
Market Capitalization more info button	$127.8 million

TTM: trailing 12 months

Paratek Pharmaceuticals share dividends

We're not expecting Paratek Pharmaceuticals to pay a dividend over the next 12 months.

Have Paratek Pharmaceuticals's shares ever split?

Paratek Pharmaceuticals's shares were split on a 1:12 basis on 30 October 2014 . So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Paratek Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Paratek Pharmaceuticals shares which in turn could have impacted Paratek Pharmaceuticals's share price.

Paratek Pharmaceuticals share price volatility

Over the last 12 months, Paratek Pharmaceuticals's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Paratek Pharmaceuticals's is 1.6978. This would suggest that Paratek Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Paratek Pharmaceuticals overview

Paratek Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co. , Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Paratek Pharmaceuticals is owned by insiders or institutions?
Currently 11.7% of Paratek Pharmaceuticals shares are held by insiders and 55.084% by institutions. How many people work for Paratek Pharmaceuticals?
Latest data suggests 268 work at Paratek Pharmaceuticals. When does the fiscal year end for Paratek Pharmaceuticals?
Paratek Pharmaceuticals's fiscal year ends in December. Where is Paratek Pharmaceuticals based?
Paratek Pharmaceuticals's address is: 75 Park Plaza, Boston, MA, United States, 02116 What is Paratek Pharmaceuticals's ISIN number?
Paratek Pharmaceuticals's international securities identification number is: US6993743029 What is Paratek Pharmaceuticals's CUSIP number?
Paratek Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 66987B103